Allergan PLC (AGN) Position Cut by Gluskin Sheff & Assoc Inc.
Gluskin Sheff & Assoc Inc. reduced its position in shares of Allergan PLC (NYSE:AGN) by 1.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,556 shares of the company’s stock after selling 2,111 shares during the period. Allergan PLC accounts for 2.2% of Gluskin Sheff & Assoc Inc.’s holdings, making the stock its 17th largest position. Gluskin Sheff & Assoc Inc.’s holdings in Allergan PLC were worth $24,855,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in AGN. Barnett & Company Inc. purchased a new position in Allergan PLC during the first quarter valued at about $111,000. Livingston Group Asset Management CO operating as Southport Capital Management bought a new stake in Allergan PLC during the second quarter worth approximately $125,000. Trust Co. of Vermont boosted its stake in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares in the last quarter. Ropes Wealth Advisors LLC boosted its stake in Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares in the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares in the last quarter. 85.19% of the stock is owned by institutional investors.
Shares of Allergan PLC (NYSE:AGN) traded down 0.03% during midday trading on Wednesday, hitting $235.71. The stock had a trading volume of 3,379,816 shares. The firm has a 50-day moving average of $241.32 and a 200 day moving average of $239.63. Allergan PLC has a 12-month low of $195.50 and a 12-month high of $322.68. The firm has a market cap of $93.33 billion, a PE ratio of 22.44 and a beta of 0.81.
Allergan PLC (NYSE:AGN) last issued its quarterly earnings data on Monday, August 8th. The company reported $3.35 EPS for the quarter, beating the Zacks’ consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The business had revenue of $3.68 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the firm posted $4.41 EPS. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, analysts expect that Allergan PLC will post $14.00 earnings per share for the current year.
AGN has been the subject of a number of recent research reports. Sanford C. Bernstein reiterated an “outperform” rating and set a $335.00 price objective on shares of Allergan PLC in a research report on Thursday, June 9th. Wells Fargo & Co. reiterated a “buy” rating on shares of Allergan PLC in a research report on Friday, June 10th. Vetr upgraded Allergan PLC from a “buy” rating to a “strong-buy” rating and set a $272.91 price objective for the company in a research report on Monday, June 13th. Piper Jaffray Cos. reiterated a “hold” rating and set a $236.00 price objective on shares of Allergan PLC in a research report on Saturday, June 18th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Allergan PLC in a research report on Saturday, June 25th. Six investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Allergan PLC currently has a consensus rating of “Buy” and a consensus price target of $302.52.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.